UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

~~June~~July 296, 2026

________________

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒

Form 40-F ☐

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 296 ~~June~~July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 22 29 June 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	67,~~200~~250,000		12,~~777~~098,~~005~~848,~~178~~921
22 June 2026	220,000	291.32	64,091,259
29 June 2026	200,000	314.24	62,847,300
23 June 2026	210,000	306.05	64,269,567
30 June 2026	200,000	318.15	63,630,624
24 June 2026	210,000	309.81	65,060,127
1 July 2026	200,000	320.42	64,083,705
25 June 2026	210,000	314.91	66,131,566
2 July 2026	200,000	325.11	65,022,718
26 June 2026	200,000	311.46	62,291,224
3 July 2026	200,000	326.71	65,342,713
Accumulated under the programme	78,250,000		2,~~098~~419,~~848~~775,~~921~~981

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 3940,194,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 263 ~~June~~July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 2223,009,179 B shares at an average share price of DKK ~~268~~270.02 32 per B share equal to a transaction value of DKK 56,~~898~~219,~~848~~775,~~910~~971.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown		Liz Skrbkova (US)
+45 3079 9289		+1 609 917 0632
[email protected]		[email protected]

Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
[email protected]		[email protected]

Ida Schaap Melvold		Sina Meyer
+45 3077 5649		+45 3079 6656
[email protected]		[email protected]

Alex Bruce		Christoffer Sho Togo Tullin
+45 3444 2613		+45 3079 1471
[email protected]		[email protected]

Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
[email protected]		[email protected]

Novo Nordisk A/SInvestor Relations	Novo Allé 12880 BagsværdDenmark	Telephone:+45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 40/ 2026
			Company announcement No 41/ 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: ~~June~~July 296, 2026 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer

Filing Compare · NOVO NORDISK A S